Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710298 | 0.91 | GRM4 (0.51) | GRM4ROCK1RXFP1GRIK1PTGDR2 | |
| SCHEMBL6707732 | 0.91 | ROCK1 (0.41) | GRM4ROCK1RXFP1GRIK1LCK | |
| SCHEMBL6707647 | 0.89 | GRM4 (0.46) | GRM4ROCK1RXFP1GRIK1PTGDR2 | |
| SCHEMBL6707599 | 0.89 | TRPA1 (0.41) | GRM4ROCK1PTGDR2LCKIMPDH2 | |
| SCHEMBL6710141 | 0.86 | GRIK1 (0.44) | RXFP1GRIK1PLCG2NSD2NHERF1 | |
| SCHEMBL6709173 | 0.86 | GRIK1 (0.44) | GRIK1PLCG2PTK2BLMNANSD2 | |
| SCHEMBL6708655 | 0.85 | NHERF1 (0.46) | RXFP1GRIK1PLCG2LMNANHERF1 | |
| SCHEMBL6710100 | 0.85 | GRM4 (0.44) | GRM4ROCK1RXFP1PLCG2PTGDR2 | |
| SCHEMBL6709877 | 0.84 | GRIK1 (0.43) | GRIK1PLCG2PTK2BLMNANSD2 | |
| SCHEMBL6713155 | 0.84 | SERPINE1 (0.48) | RXFP1GRIK1PLCG2LMNANSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GRM4 4668/4885ROCK1 4830/4885RXFP1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.